NKARTA INC (NKTX)
Health Care · biotechnology · NASDAQ
Nkarta is a clinical-stage biotechnology company pioneering off-the-shelf, engineered natural killer (NK) cell therapies to treat autoimmune diseases by depleting pathogenic B cells.
What NKARTA INC does
Nkarta is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. Its lead program, NKX019, is a CAR-NK product candidate designed to target CD19-positive B cells for the treatment of various autoimmune diseases, aiming to induce disease remission by resetting the immune system.
Recent developments
In April 2026, the company reached agreement with the FDA on protocol amendments for the Ntrust-1 and Ntrust-2 trials to enable outpatient administration of NKX019 and include a rheumatoid arthritis cohort. In August 2026, the company reported that enrollment continues across all indications at the 4 billion cell dose level, and it expects to present initial clinical data later in 2026.
From NKARTA INC's filing of 2026-08-10.
Themes: cell therapy, autoimmune diseases, NK cell therapy, B-cell depletion, off-the-shelf immunotherapy
Fundamentals
- Price$2.22 as of 2026-10-08 close
- Market cap$159M as of 2026-08-05 (share count; price 2026-10-08)
- 1-year return+6.2% 2025-10-08 close $2.09 → 2026-10-08 close $2.22
- P/En/a negative earnings
- ROE-33.3% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Beta1.25 as of 2026-09-03
- Last reported earnings2026-08-10 SEC EDGAR Form 8-K (Item 2.02)
How NKTX compares in its sector
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How NKARTA INC looks technically
NKARTA INC (NKTX) is trading 12.1% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 160 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 25, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 30, neither overbought (above 70) nor oversold (below 30). It just made a new 20-day low, its first since 2026-08-05, breaking below its recent trading range. It is 40.3% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 12.1% below its 200-day average, the long-term trend line — a long-term downtrend | -12.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $2.60 | $2.60 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $2.53 | $2.53 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 30 calendar days ago — the swings before that are what the structure reading is measured on | 30 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 3.3. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 160 trading days ago — a "golden cross", a bullish long-term signal | 160 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 25, with sellers in control | 25.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 30, neither overbought (above 70) nor oversold (below 30) | 30.2 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($2.16 to $2.99) — its "stochastic" reading is 7 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 7.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 16 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $3.72 | $3.72 |
|---|---|---|
| From the 52-week high | it is 40.3% below its 52-week high (its highest price of the past year) | -40.3% |
| Above the 52-week low | it is 30.6% above its 52-week low (its lowest price of the past year) | +30.6% |
| Below the 52-week high | it is 40.3% below its highest point of the past year | 40.3% |
| Since a 20-day breakout | it just made a new 20-day low, its first since 2026-08-05, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day low about 49 trading days ago | 49 sessions |
| All-time high | its highest closing price on record is $58.78 (set on 2021-02-22) | $58.78 |
| Given back of the 52-week move | over the past year its closes ranged ($1.73 to $3.67), and it has given back well over two thirds of its rise from last year’s low — 75% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $2.41 to $2.47. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 74.7% |
| From the all-time high | it is 96.2% below its all-time high | -96.2% |
| Nearest price level | it is trading 1.2% above a support level at $2.19 — a price it turned at three times since 2025-01-15, most recently on 2026-01-08. Since 2024-10-08 it has 5 such levels below the current price and 8 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.2% |
| All-time low | its lowest closing price on record is $1.28 (set on 2023-10-02) | $1.28 |
| Above the all-time low | it is 73.4% above its all-time low | +73.4% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 54th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1667 between its high and its low — about 7.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1667 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $2.25 and $3.12 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $2.25 – $2.69 – $3.12 |
| Typical daily range (% of price) | its price moves about 7.5% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.5% |
| Stretch from the 200-day average | it is trading 1.8 daily ranges below its 200-day average price (12.1% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.8 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.22× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-08 1.8% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -1.8% |
|---|---|---|
| Gap filled | a 2.2% gap down opened on 2026-10-07 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 1 session ago |
Price streaks
1
| Closing streak | it has closed lower 4 sessions in a row, a -13.79% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 4 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 32.3 percentage points (the stock lost 31.3% while the market gained 1.0%) | -32.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 43.3 percentage points (the stock lost 39.5% while the market gained 3.8%) | -43.3% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 23.4 percentage points (the stock lost 5.9% while the market gained 17.5%) | -23.4% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 8.8 percentage points (the stock gained 6.2% while the market gained 15.0%) | -8.8% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 11% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 17.0% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -11.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 15% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $2.62 — a volume-weighted average of daily closes over 188 sessions, not a true tick-by-tick VWAP. | -15.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 17% below the average price paid since it last reported on 2026-08-10 (its 10-Q), so the typical buyer over that stretch is under water. That average is $2.69 — a volume-weighted average of daily closes over 43 sessions, not a true tick-by-tick VWAP. | -17.4% |
Price levels it has turned at before
NKTX last closed at $2.22 on 2026-10-08. Since 2024-10-08 it has turned at 5 prices below its last close and 8 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $2.19 | Support | 1.2% below the last close | turned there three times · 2025-01-15 to 2026-01-08 |
| $2.28 | Resistance | 2.7% above the last close | turned there twice · 2025-04-23 to 2025-09-08 |
| $2.34 | Resistance | 5.3% above the last close | turned there three times · 2025-02-19 to 2025-07-30 |
| $2.08 | Support | 6.3% below the last close | turned there twice · 2024-12-19 to 2025-06-10 |
| $2.38 | Resistance | 7.4% above the last close | turned there twice · 2024-11-19 to 2026-06-08 |
| $2.03 | Support | 8.4% below the last close | turned there twice · 2025-10-07 to 2026-07-31 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $3.30.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 3 trading days, since 2026-10-06.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · lagging the market · Printed a doji candle · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.14 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$10.83 range $9.00 – $14.00; median $10.50
Analyst estimates, as of 2026-10-04. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for NKTX
- Consensus EPS estimate-$0.3833 next reporting period, as of 2026-10-04
- Estimate change, 30 days-$0.02 from -$0.3633, on 2026-08-30, 35-day window
- Readings revised upward0% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["The company is a clinical-stage enterprise with no approved products and a history of operating losses, requiring significant additional capital to fund operations into the future.","Development of allogeneic cell therapies involves complex manufacturing and regulatory challenges, and clinical trial outcomes for NKX019 remain uncertain."]
What changed in the latest 10-Q
AI-assisted comparison of NKTX's 10-Q filed 2026-05-12 against the prior one filed 2025-11-10.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-12) adds: In April 2026, agreement with FDA on protocol amendments to both Ntrust-1 and Ntrust-2 trials to enable outpatient administration, reducing post-dose monitoring from 24 hours to 2 hours, and to provide option to re-dose patients. Protocol amendments also provided for addition of RA cohort to Ntrust-2 and removal of geographic monitoring requirements. Amendments were submitted to FDA and IRBs and approved by central IRB.
- Newer filing (2026-05-12) specifies that Ntrust-1 and Ntrust-2 are Phase 1/2 clinical trials (versus Phase 1 only in older filing)
- Newer filing (2026-05-12) adds RA (rheumatoid arthritis) as indication in Ntrust-2 trial description in Overview section
- Removed:
- Older filing (2025-11-10) contains: In March 2025, workforce reduction announced as result of strategic priorities review
- Older filing (2025-11-10) states that pMN was announced as addition to Ntrust-1 in May 2025, and modification of LD conditioning announced at that time
- Older filing (2025-11-10) mentions NKX019 being studied in another multi-center Phase 1 clinical trial for B-cell malignancies
- Older filing (2025-11-10) references 'smaller reporting company' and 'emerging growth company' exemptions under JOBS Act (newer filing omits JOBS Act reference and specific exemption language)
- Reworded:
- Older filing states technologies 'that enable us to generate...freeze, store, and thaw' versus newer filing states 'designed to generate...enhance NK cell fitness to support scalable, off the shelf administration' (omits specific freeze/store/thaw language)
- Older filing references Annual Report on Form 10-K 'filed with the SEC on March 26, 2025 for the fiscal year ended December 31, 2024' versus newer filing references 'filed with the SEC on March 25, 2026 for the fiscal year ended December 31, 2025'
- Older filing refers to 'emerging growth company' exemptions versus newer filing refers to 'smaller reporting company' exemptions
- Notes:
- Text in both filings is truncated at end, limiting full comparison of later sections
- Changes reflect different fiscal periods (FY2024 versus FY2025) and different quarterly reporting periods (Q3 2025 versus Q1 2026)
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 180 days · read to 2026-10-040 buys · 1 sell ($4813) — 1 selling insider
Most recent open-market transaction: 2026-06-18. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about NKTX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding NKTX as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 13,405,405
- Reported value $37,937,295
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about NKTX's institutional holders → See what each manager we track holds →
Short interest (FINRA)
NKTX had 3,506,533 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
NKTX had 4.90% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.46 days to cover at the same settlement.
- Reported short interest (shares) 3,506,533
- Short interest (% of shares outstanding) 4.90%
- Prior settlement (shares) 3,438,080
- Reported change 1.99%
- Days to cover (reported) 5.46
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Fate Therapeutics (FATE)
- Mustang Bio (MBIO)
- Caribou Biosciences (CRBU)
- CRISPR Therapeutics (CRSP)
- Intellia Therapeutics (NTLA)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare NKTX vs…
NKARTA INC is found in…
Frequently asked questions
What does NKARTA INC (NKTX) do?
Nkarta is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. Its lead program, NKX019, is a CAR-NK product candidate designed to target CD19-positive B cells for the treatment of various autoimmune diseases, aiming to induce disease remission by resetting the immune system.
What sector is NKARTA INC (NKTX) in?
NKARTA INC (NKTX) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are NKARTA INC's (NKTX) competitors?
Notable peers of NKARTA INC (NKTX) include Fate Therapeutics, Mustang Bio, Caribou Biosciences, CRISPR Therapeutics and Intellia Therapeutics. This peer set is informational only — not financial advice.
Is NKARTA INC (NKTX) overbought or oversold right now?
NKARTA INC (NKTX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 30, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on NKTX come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.